GSK and Hengrui Pharma Announce $12.5 Billion Multi-Asset Collaboration
GSK and Hengrui Pharma have entered into agreements to develop up to 12 innovative medicines, including a potential best-in-class PDE3/4 inhibitor for COPD, with GSK paying $500 million upfront and the potential for up to $12 billion in milestone payments, aiming to expand their pipelines in respiratory, immunology, inflammation, and oncology.